PRESS RELEASES

Date Title and Summary View
Jun 10, 2012
Summary ToggleZafgen Announces Additional Weight Loss and Cardiometabolic Data from Phase 1 Studies of Beloranib in Obesity at American Diabetes Association’s 72nd Scientific Sessions®

Results Show Treatment with Beloranib Resulted in Weight Loss and Corresponding Reductions in Multiple Cardiometabolic Risk Factors in Severely Obese Subjects

Summary ToggleZafgen Announces Additional Weight Loss and Cardiometabolic Data from Phase 1 Studies of Beloranib in Obesity at American Diabetes Association’s 72nd Scientific Sessions®
Oct 13, 2011
Summary ToggleZafgen Appoints Business Development Veteran Frances K. Heller to Board of Directors Summary ToggleZafgen Appoints Business Development Veteran Frances K. Heller to Board of Directors
Sep 28, 2011
Summary ToggleZafgen to Present at The Obesity Society 29th Annual Scientific Meeting Summary ToggleZafgen to Present at The Obesity Society 29th Annual Scientific Meeting
Sep 21, 2011
Summary ToggleZafgen Appoints Industry Executive Dennis Kim, M.D., M.B.A., to Chief Medical Officer Summary ToggleZafgen Appoints Industry Executive Dennis Kim, M.D., M.B.A., to Chief Medical Officer
Jul 7, 2011
Summary ToggleZafgen Secures $33 Million Series C Financing

Proceeds to Advance Zafgen’s Lead Compound for Severe Obesity into Phase 2 Clinical Studies

Summary ToggleZafgen Secures $33 Million Series C Financing
Jun 24, 2011
Summary ToggleZafgen Announces Cardiovascular Data from Phase 1b Study of ZGN-433 in Obesity at American Diabetes Association Annual Meeting

Results Show MetAP2 Inhibitor Treatment Improves Cardiovascular Risk Markers in Severely Obese Subjects

Company Also Announces Initiation of Dose Escalation Trial in Obese Women

Summary ToggleZafgen Announces Cardiovascular Data from Phase 1b Study of ZGN-433 in Obesity at American Diabetes Association Annual Meeting
Apr 8, 2011
Summary ToggleZafgen to Present at BioCentury Future Leaders in the Biotech Industry Conference Summary ToggleZafgen to Present at BioCentury Future Leaders in the Biotech Industry Conference
Jan 5, 2011
Summary ToggleZafgen Announces Positive Topline Phase 1b Data for ZGN-433 in Obesity

Findings Show MetAP2 Inhibition Treatment Drives Significant Weight Loss with Excellent Tolerability and Favorable Metabolic Effects

Summary ToggleZafgen Announces Positive Topline Phase 1b Data for ZGN-433 in Obesity
Jun 26, 2010
Summary ToggleZafgen Presents Data on a New Class of Medicines to Treat Obesity at the American Diabetes Association Annual Meeting

Data Show Treatment with MetAP2 Inhibitor Eliminates Excess Body Fat through Regulation of Fat Metabolism and Food Intake and Normalizes Glucose Tolerance in Preclinical Models

Summary ToggleZafgen Presents Data on a New Class of Medicines to Treat Obesity at the American Diabetes Association Annual Meeting
Oct 26, 2009
Summary ToggleZafgen, Inc. to Present at Upcoming Conferences Summary ToggleZafgen, Inc. to Present at Upcoming Conferences